Skip to content

Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure

Post-approval Study of New Enrolment Patients Undergoing Bilateral Treatment With the VisuMax SMILE Procedure

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05740293
Enrollment
186
Registered
2023-02-23
Start date
2022-04-05
Completion date
2025-08-25
Last updated
2025-08-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Astigmatism, Myopia

Brief summary

The objective of the post-approval study (PAS) is to assess patient experience of visual symptoms 6 months after bilateral treatment with the VisuMax SMILE procedure as measured by a patient questionnaire.

Detailed description

This is a prospective, multicenter, single arm, open-label, observational study of newly enrolled patients undergoing bilateral treatment with the approved SMILE procedure for the reduction or elimination of myopia with astigmatism. Patients complete a self-administered patient questionnaire preoperatively and 6 months postoperatively. Each patient's preoperative status is serving as the control for postoperative endpoints.

Interventions

PROCEDUREVisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism

Bilateral treatment with the approved VisuMax SMILE procedure for the reduction or elimination of myopia with astigmatism.

Sponsors

Carl Zeiss Meditec, Inc.
Lead SponsorINDUSTRY

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
22 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Eligible for the approved VisuMax SMILE procedure according to the Professional Use Information, i.e. * Spherical refractive error (in minus cylinder format) from -1.00 D through -10.00 D; * Refraction spherical equivalent not greater in magnitude than 10.00 D; * Minimum age of 22 years; * Documentation of stable manifest refraction over the past year as demonstrated by a change in sphere and cylinder of ≤ 0.50 D in magnitude. * Good candidate for SMILE based on the surgeon's assessment of medical and ophthalmic health, cognitive function, and physical and social limitations * Intended bilateral SMILE treatment for the correction of myopia with astigmatism (-0.75 to -3.00 D) * Both eyes targeted for the full distance manifest spherocylindrical refraction * Fluent English in speaking and reading * Willingness and ability to return for 6-month postoperative examination * Signed informed consent

Exclusion criteria

* Presence of any of the contraindications of the approved SMILE procedure for the reduction or elimination of myopia with astigmatism, i.e. * a residual stromal bed thickness that is less than 250 microns from the corneal endothelium; * abnormal corneal topographic findings, e.g. keratoconus, pellucid marginal degeneration; * ophthalmoscopic signs of progressive or unstable myopia or keratoconus (or keratoconus suspect); * irregular or unstable (distorted/not clear) corneal mires on central keratometry images; * severe dry eye; * active eye infection or inflammation; * recent herpes eye infection or problems resulting from past infection; * active autoimmune disease or connective tissue disease; * uncontrolled diabetes; * uncontrolled glaucoma. * Previous treatment with any form of refractive surgery

Design outcomes

Primary

MeasureTime frameDescription
Development of clinically relevant visual symptoms via questionnaire responses6 months* Proportion of subjects that developed very or extremely bothersome visual symptoms from preoperative (with optical correction) to 6 months postoperatively (without optical correction) * Proportion of subjects that developed difficulty performing daily activities (2 highest categories) due to visual symptoms from preoperative (with optical correction) to 6 months postoperatively (without optical correction)

Secondary

MeasureTime frameDescription
Resolution of clinically relevant visual symptoms via questionnaire responses6 months* Proportion of subjects that showed resolution of very or extremely bothersome visual symptoms from preoperative (with optical correction) to 6 months postoperatively (without optical correction) * Proportion of subjects that showed resolution of difficulty performing daily activities (2 highest categories) due to visual symptoms from preoperative (with optical correction) to 6 months postoperatively (without optical correction)
Development and resolution of all visual symptoms via questionnaire responses6 months* Proportion of subjects that developed visual symptoms from preoperative (with optical correction) to 6 months postoperatively (without optical correction) * Proportion of subjects that showed resolution of visual symptoms from preoperative (with optical correction) to 6 months postoperatively (without optical correction)
Dry eye via questionnaire responses6 months* Proportion of subjects that developed dry eye symptoms as compared to their preoperative status (OSDI score from normal at preoperative to abnormal at 6 months; categorized according to Miller et al. 2010) * Proportion of subjects that showed resolution of dry eye symptoms as compared to their preoperative status (OSDI score from abnormal at preoperative to normal at 6 months; categorized according to Miller et al. 2010)
Satisfaction via questionnaire responses6 months* Proportion of patients satisfied with their vision after the SMILE procedure (who responded completely satisfied, very satisfied, or somewhat satisfied to the corresponding questionnaire item) * Proportion of patients satisfied with the SMILE procedure (based on a score ≥ 40 in the corresponding 8-item questionnaire domain)

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026